Pharmaceutical Preparations · DE · CIK 1228627
Opus Genetics develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases
Comparable business profile · signals at a glance
In the 90 days to Mar 16, 2026: 1 insider bought $324K · 4 sold $181K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Magrath GeorgeChief Executive Officer | Sell | 24,438 | $5.21 | $127K |
| Mar 16, 2026 | Schachle Joseph KChief Operating Officer | Sell | 3,719 | $5.25 | $20K |
| Mar 16, 2026 | Jayagopal AshwathChief Scientific & Dev. Ofc. | Sell | 3,719 | $5.12 | $19K |
| Mar 16, 2026 | Zaremba Rabourn AmyHead of Fin. Quality Assurance | Sell | 2,816 | $5.25 | $15K |
| Dec 29, 2025 | Gallagher CamDirector | Buy | 83,000 | $1.97 | $164K |
| Dec 29, 2025 | Gallagher CamDirector | Buy | 81,000 | $1.98 | $160K |
| Dec 9, 2025 | Foundation Fighting Blindness Retinal Degeneration FundDirector,Other | Sell | 4,000,000 | $2.15 | $8.6M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.